Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
03692 HANSOH PHARMA
RTNominal unchange15.480 0.000 (0.000%)
Research Report

16/07/2019 15:41

[I-bank focus]Goldman rates Hansoh Pharma (03692) HK$27.5

[ET Net News Agency, 16 July 2019] Goldman Sachs initiated coverage on Hansoh
Pharmaceutical (03692) with a "buy" rating and a target price of HK$27.5.
The research house said Hansoh Pharma is a leading specialty drugmaker and transitioning
to a "generics+innovation" model, similar to Hengrui (Shanghai: 600276) and Sino Biopharm
(01177).
Despite near-term uncertainty and concerns about generics amid policy changes, Hansoh's
leadership position and diversified portfolio would make it a key beneficiary in any major
generics market consolidation in China, Goldman said.
While some core products may face pricing pressure due to centralized procurement, this
would be partially offset by volume ramp-up from its seven products listed in the 2017
NRDL and new generics (20-30 in 2019/20). It forecast 2018-21 sales CAGR of 26% and
earnings CAGR of 30%, with its emerging novel drug portfolio as a key driver. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.